FDA Fast Track Designation (FTD) aims to accelerate the review process of high-value assets, and ISM6331 marks Insilico’s first FTD, recognizing the clinical potential in advanced mesothelioma.

ISM6331 is a novel, potential best-in-class, pan-TEAD inhibitor engineered via Chemistry42 to restore Hippo pathway balance, and its Phase I first-in-human data has been accepted for a brief oral presentation at ESMO 2026.

The FTD grants ISM6331 enhanced FDA engagement to accelerate the clinical development processes, alongside eligibility for Rolling Review, Accelerated Approval, and Priority Review, if relevant criteria are met.

Air filters are essential for protecting human health by removing harmful particulate matter from the air. However, conventional filters often struggle to securely retain captured particles, allowing some to detach over time and reducing filtration performance. To address this longstanding challenge, researchers from Chung-Ang University and Pusan National University developed an innovative self-renewing adhesive coating designed to improve particle retention, paving the way for more efficient and durable air filtration technologies.

Oligonucleotide synthesis is fundamental to genetic analysis, biological research, and nucleic acid therapeutics. However, current methods rely on moisture-sensitive building blocks and require a dedicated oxidation step with each chain elongation, making it operationally complex. To address this, researchers from Japan have developed a new approach using phosphorofluoridate building blocks, enabling efficient oxidation-free oligonucleotide synthesis. This advance simplifies the synthetic workflow, offering a faster and more reliable platform for nucleotide chemistry.